Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience
Abstract Nivolumab is an effective and safe treatment in HCC.
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-04-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.3970 |
id |
doaj-e758a507356a45148acf63bdc32d8cbc |
---|---|
record_format |
Article |
spelling |
doaj-e758a507356a45148acf63bdc32d8cbc2021-05-15T18:35:45ZengWileyClinical Case Reports2050-09042021-04-01942162216710.1002/ccr3.3970Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experienceOuissam Al jarroudi0Hamed Chaabouni1Ayhan Ulusakarya2Wathek Almohamad3Yusuf Gumus4Emma Goldschmidt5Said Afqir6Jean‐francois Morère7Medical Oncology Department AP‐HPPaul Brousse Hospital Villejuif FranceMedical Oncology Department AP‐HPPaul Brousse Hospital Villejuif FranceMedical Oncology Department AP‐HPPaul Brousse Hospital Villejuif FranceMedical Oncology Department AP‐HPPaul Brousse Hospital Villejuif FranceMedical Oncology Department AP‐HPPaul Brousse Hospital Villejuif FranceMedical Oncology Department AP‐HPPaul Brousse Hospital Villejuif FranceMedical Oncology Department University Hospital Mohammed VI‐Oujda Oujda MoroccoMedical Oncology Department AP‐HPPaul Brousse Hospital Villejuif FranceAbstract Nivolumab is an effective and safe treatment in HCC.https://doi.org/10.1002/ccr3.3970clinical outcomeshepatocellular carcinomanivolumabsurvival |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ouissam Al jarroudi Hamed Chaabouni Ayhan Ulusakarya Wathek Almohamad Yusuf Gumus Emma Goldschmidt Said Afqir Jean‐francois Morère |
spellingShingle |
Ouissam Al jarroudi Hamed Chaabouni Ayhan Ulusakarya Wathek Almohamad Yusuf Gumus Emma Goldschmidt Said Afqir Jean‐francois Morère Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience Clinical Case Reports clinical outcomes hepatocellular carcinoma nivolumab survival |
author_facet |
Ouissam Al jarroudi Hamed Chaabouni Ayhan Ulusakarya Wathek Almohamad Yusuf Gumus Emma Goldschmidt Said Afqir Jean‐francois Morère |
author_sort |
Ouissam Al jarroudi |
title |
Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience |
title_short |
Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience |
title_full |
Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience |
title_fullStr |
Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience |
title_full_unstemmed |
Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience |
title_sort |
anti‐programmed death‐1 therapy in advanced hepatocellular carcinoma: a real‐world experience |
publisher |
Wiley |
series |
Clinical Case Reports |
issn |
2050-0904 |
publishDate |
2021-04-01 |
description |
Abstract Nivolumab is an effective and safe treatment in HCC. |
topic |
clinical outcomes hepatocellular carcinoma nivolumab survival |
url |
https://doi.org/10.1002/ccr3.3970 |
work_keys_str_mv |
AT ouissamaljarroudi antiprogrammeddeath1therapyinadvancedhepatocellularcarcinomaarealworldexperience AT hamedchaabouni antiprogrammeddeath1therapyinadvancedhepatocellularcarcinomaarealworldexperience AT ayhanulusakarya antiprogrammeddeath1therapyinadvancedhepatocellularcarcinomaarealworldexperience AT wathekalmohamad antiprogrammeddeath1therapyinadvancedhepatocellularcarcinomaarealworldexperience AT yusufgumus antiprogrammeddeath1therapyinadvancedhepatocellularcarcinomaarealworldexperience AT emmagoldschmidt antiprogrammeddeath1therapyinadvancedhepatocellularcarcinomaarealworldexperience AT saidafqir antiprogrammeddeath1therapyinadvancedhepatocellularcarcinomaarealworldexperience AT jeanfrancoismorere antiprogrammeddeath1therapyinadvancedhepatocellularcarcinomaarealworldexperience |
_version_ |
1721440527655632896 |